Biodexa Pharmaceuticals’ (BDRX) stock took a significant dive on Thursday despite positive updates from its ongoing MAGIC-1 study evaluating MTX110 in recurrent glioblastoma (rGBM). While the data suggests potential for a new treatment option, the stock’s reaction highlights investor uncertainty and market volatility.
Results for: Glioblastoma
For the first time, scientists have tested an mRNA vaccine in a patient with glioblastoma, an aggressive type of brain cancer. The vaccine triggered a strong immune response, offering hope for a new treatment approach. The vaccine was created by extracting genetic material from the patient’s tumor and replicating it to make mRNA, which then instructed the body to attack the cancer cells.